Knight Capital Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Knight Capital Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$2.9M	Buy	+52,008	New	+$3.24M	0.05%	350

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Knight Capital Group's BMRN Position: Q2 2013 in Review

Knight Capital Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2013: 52,008 shares worth $2.9M. The stake represents 0.05% of the portfolio and ranks #350 among its holdings.

280 funds tracked by Wall St. Rank hold BMRN as of Q2 2013.

Knight Capital Group held 52,008 shares of BioMarin Pharmaceuticals worth $2.9M as of Q2 2013.
BioMarin Pharmaceuticals was a new Knight Capital Group position in Q2 2013.
BioMarin Pharmaceuticals made up 0.05% of Knight Capital Group's portfolio in Q2 2013, its #350 holding.
280 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.